Dr. Coles is a founding investor and the chairman and chief executive officer of Yumanity Therapeutics, a Cambridge, MA-based biotechnology company focused on transforming drug discovery for neurodegenerative diseases caused by protein misfolding such as Alzheimer's, Parkinson's and amyotrophic lateral sclerosis (ALS).Dr. Coles also serves as chairman and chief executive officer of TRATE Enterprises,LLC, a privately held company.
Previously, Dr. Coles was chairman and chief executive officer of Onyx Pharmaceuticals, Inc., which was acquired by Amgen in late 2013. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company's international presence outside of the U.S. Prior to joining Onyx in 2008, he was president, chief executive officer and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS Pharmaceuticals in 2005, Dr. Coles was senior vice president of commercial operations at Vertex Pharmaceuticals Inc., and earlier, held a number of executive positions at Bristol-Myers Squibb Company and positions of increasing responsibility at Merck & Co.,Inc.
Educated at Johns Hopkins University, he earned an M.D. from Duke University and a master's degree in public health from Harvard University. He completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School.
Dr. Coles currently serves as chairman of the board of CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for patients with serious diseases. He also serves as a member of the board of directors of McKesson Corporation (NYSE: MCK) and Regeneron (NASDAQ:REGN) and is a member of the board of trustees for Johns Hopkins University and Johns Hopkins Medicine. Dr. Coles also serves as a member of the Council for the Smithsonian's National Museum of African American History and Culture in Washington, D.C.; a member of the board of trustees for The Metropolitan Museum of Art in New York City; a member of the board of directors of the Council on Foreign Relations, an independent, nonpartisan membership organization, think tank, and publisher; and a member on the Harvard Medical School Advisory Board.